Franco-Fuquen P, Figueroa-Aguirre J, Martinez D, Moreno-Cortes E, Garcia-Robledo J, Vargas-Cely F
J Transl Autoimmun. 2025; 10:100264.
PMID: 39931050
PMC: 11808717.
DOI: 10.1016/j.jtauto.2024.100264.
Minguet S, Maus M, Schamel W
Nat Rev Immunol. 2024; 25(3):212-224.
PMID: 39433885
DOI: 10.1038/s41577-024-01093-7.
Wang Y, Li J, Wang Z, Liu Y, Wang T, Zhang M
Cell Prolif. 2024; 57(11):e13683.
PMID: 38830795
PMC: 11533075.
DOI: 10.1111/cpr.13683.
Eichholz K, Fukazawa Y, Peterson C, Haeseleer F, Medina M, Hoffmeister S
J Clin Invest. 2024; 134(7).
PMID: 38557496
PMC: 10977982.
DOI: 10.1172/JCI169309.
Morte-Romea E, Pesini C, Pellejero-Sagastizabal G, Letona-Gimenez S, Martinez-Lostao L, Aranda S
Front Immunol. 2024; 15:1289303.
PMID: 38352878
PMC: 10861799.
DOI: 10.3389/fimmu.2024.1289303.
Antigen-induced chimeric antigen receptor multimerization amplifies on-tumor cytotoxicity.
Sun Y, Yang X, Yang S, Lyu Y, Zhang B, Liu K
Signal Transduct Target Ther. 2023; 8(1):445.
PMID: 38062078
PMC: 10703879.
DOI: 10.1038/s41392-023-01686-z.
CAR-T-Cell Therapy in Multiple Myeloma: B-Cell Maturation Antigen (BCMA) and Beyond.
Mishra A, Gupta A, Dagar G, Das D, Chakraborty A, Haque S
Vaccines (Basel). 2023; 11(11).
PMID: 38006053
PMC: 10674477.
DOI: 10.3390/vaccines11111721.
Targeting the HIV reservoir: chimeric antigen receptor therapy for HIV cure.
Li S, Wang H, Guo N, Su B, Lambotte O, Zhang T
Chin Med J (Engl). 2023; 136(22):2658-2667.
PMID: 37927030
PMC: 10684145.
DOI: 10.1097/CM9.0000000000002904.
Strategies for enhancing CAR T cell expansion and persistence in HIV infection.
Rothemejer F, Lauritsen N, Sogaard O, Tolstrup M
Front Immunol. 2023; 14:1253395.
PMID: 37671164
PMC: 10475529.
DOI: 10.3389/fimmu.2023.1253395.
Harnessing the potential of CAR-T cell therapy: progress, challenges, and future directions in hematological and solid tumor treatments.
Dagar G, Gupta A, Masoodi T, Nisar S, Merhi M, Hashem S
J Transl Med. 2023; 21(1):449.
PMID: 37420216
PMC: 10327392.
DOI: 10.1186/s12967-023-04292-3.
Co-opting signalling molecules enables logic-gated control of CAR T cells.
Tousley A, Rotiroti M, Labanieh L, Rysavy L, Kim W, Lareau C
Nature. 2023; 615(7952):507-516.
PMID: 36890224
PMC: 10564584.
DOI: 10.1038/s41586-023-05778-2.
Development of HIV-Resistant CAR T Cells by CRISPR/Cas-Mediated CAR Integration into the Locus.
Rothemejer F, Lauritsen N, Juhl A, Schleimann M, Konig S, Sogaard O
Viruses. 2023; 15(1).
PMID: 36680242
PMC: 9862650.
DOI: 10.3390/v15010202.
Decoding CAR T cell phenotype using combinatorial signaling motif libraries and machine learning.
Daniels K, Wang S, Simic M, Bhargava H, Capponi S, Tonai Y
Science. 2022; 378(6625):1194-1200.
PMID: 36480602
PMC: 10026561.
DOI: 10.1126/science.abq0225.
speedingCARs: accelerating the engineering of CAR T cells by signaling domain shuffling and single-cell sequencing.
Castellanos-Rueda R, Di Roberto R, Bieberich F, Schlatter F, Palianina D, Nguyen O
Nat Commun. 2022; 13(1):6555.
PMID: 36323661
PMC: 9630321.
DOI: 10.1038/s41467-022-34141-8.
CAR-T cells leave the comfort zone: current and future applications beyond cancer.
Mazzi M, Hajdu K, Ribeiro P, Bonamino M
Immunother Adv. 2022; 1(1):ltaa006.
PMID: 36284896
PMC: 9585679.
DOI: 10.1093/immadv/ltaa006.
A novel multimeric sCD19-streptavidin fusion protein for functional detection and selective expansion of CD19-targeted CAR-T cells.
Lian H, Jiang J, Wang Y, Yu X, Zheng R, Long J
Cancer Med. 2022; 11(15):2978-2989.
PMID: 35621033
PMC: 9359867.
DOI: 10.1002/cam4.4657.
Pre-clinical data supporting immunotherapy for HIV using CMV-HIV-specific CAR T cells with CMV vaccine.
Guan M, Lim L, Holguin L, Han T, Vyas V, Urak R
Mol Ther Methods Clin Dev. 2022; 25:344-359.
PMID: 35573050
PMC: 9062763.
DOI: 10.1016/j.omtm.2022.04.007.
Evolving Strategies to Eliminate the CD4 T Cells HIV Viral Reservoir CAR T Cell Immunotherapy.
York J, Gowrishankar K, Micklethwaite K, Palmer S, Cunningham A, Nasr N
Front Immunol. 2022; 13:873701.
PMID: 35572509
PMC: 9098815.
DOI: 10.3389/fimmu.2022.873701.
Emerging CAR T Cell Strategies for the Treatment of AML.
Vishwasrao P, Li G, Boucher J, Smith D, Hui S
Cancers (Basel). 2022; 14(5).
PMID: 35267549
PMC: 8909045.
DOI: 10.3390/cancers14051241.
CAR/CXCR5-T cell immunotherapy is safe and potentially efficacious in promoting sustained remission of SIV infection.
Pampusch M, Abdelaal H, Cartwright E, Molden J, Davey B, Sauve J
PLoS Pathog. 2022; 18(2):e1009831.
PMID: 35130312
PMC: 8853520.
DOI: 10.1371/journal.ppat.1009831.